Table of Contents
Myrbetriq, which contains mirabegron, comes in dosage two dosage options: Myrbetriq 25 mg and 50 mg. This medication is used to treat overactive bladder (OAB) in adults.
Myrbetriq's benefits include:
- Improves symptoms of overactive bladder.
- Works differently than other medications for overactive bladder.
- Can be used in combination with another overactive bladder medication.
Myrbetriq is very commonly prescribed in the U.S. due to its effectiveness and tolerability. Read on to learn more about its major benefits.
Myrbetriq for Overactive Bladder Symptoms
Anyone who has experienced overactive bladder can attest to the unpleasant nature of its symptoms. Rather than a disease, OAB refers to a collection of urinary symptoms. These symptoms may include:
- Feeling a sudden urge to urinate.
- Experiencing difficulty controlling the urge to urinate.
- Urgency incontinence (unintentional loss of urine after feeling the urge to urinate).
- Nocturia (waking up more than twice during the night to urinate). 
Unfortunately, OAB affects a large number of U.S. adults. As many as 40 percent of men and 30 percent of women experience symptoms of OAB.
With that in mind, it's not hard to see why Myrbetriq's ability to relieve the symptoms of OAB is a significant benefit. Myrbetriq works quickly to provide improvements within the first several weeks of treatment.
Unique Benefits of Myrbetriq
Myrbetriq is unique in that it's the first and only medication in its class to target beta-3 receptors via the sympathetic nerve pathway.
Beta-3 receptors are only found in the urinary bladder, gallbladder and brown fat tissue. This means that by targeting beta-3 receptors in particular, Myrbetriq is thus able to target the bladder.
So, why beta-3 receptors? When those receptors are stimulated via Myrbetriq, the smooth muscle surrounding the bladder relaxes. In this way, the bladder is able to hold more urine, thereby allowing patients to urinate less frequently and experience fewer symptoms of urgency and leakage. 
Benefits of Myrbetriq Combination Therapy
Myrbetriq was first approved by the Food and Drug Administration (FDA) for the treatment of overactive bladder in 2012. Six years later, the FDA also approved Myrbetriq to treat OAB in combination with solifenacin succinate.
Solifenacin succinate is another type of overactive bladder medication that's marketed under the brand name Vesicare, among others. Unlike Myrbetriq, solifenacin succinate works by stimulating the muscarinic receptors.
This also serves to relax the muscle surrounding the bladder, albeit via different receptors.
So, by taking Myrbetriq and solifenacin succinate together, people with OAB symptoms may experience a great improvement in their symptoms than if they were taking just one of those medications alone.
OAB may be a common condition, but medications like Myrbetriq can help the millions of people who experience its symptoms.
Buy your Myrbetriq medication online now and have it delivered straight to your door.
DISCLAIMER: The information in the article is not meant to be used for treatment or diagnosis. It is designed for general awareness and for information purposes only. Always consult a medical professional for your specific healthcare needs.